2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
898 0
SM ISO690:2012
GALIE, Nazzareno, NOI, Autori, BOTNARU, Victor. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. In: European Heart Journal, 2016, vol. 37, pp. 67-119. ISSN 0195-668X. DOI: https://doi.org/10.1093/eurheartj/ehv317
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
European Heart Journal
Volumul 37 / 2016 / ISSN 0195-668X

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

DOI: https://doi.org/10.1093/eurheartj/ehv317

Pag. 67-119

Galie Nazzareno1, Noi Autori, Botnaru Victor2
 
1 University of Bologna,
2 ”Nicolae Testemițanu” State University of Medicine and Pharmacy
 
Disponibil în IBN: 24 aprilie 2019


Cuvinte-cheie
Chronic thromboembolic pulmonary hypertension, congenital heart disease, connective tissue disease, Endothelin Receptor Antagonists, Guidelines, heart failure, Left heart disease, lung disease, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Pulmonary arterial hypertension, pulmonary hypertension, Respiratory failure

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-76463</cfResPublId>
<cfResPublDate>2016-01-01</cfResPublDate>
<cfStartPage>67</cfStartPage>
<cfISSN>0195-668X</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/76463</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>Chronic thromboembolic pulmonary hypertension; congenital heart disease; connective tissue disease; Endothelin Receptor Antagonists; Guidelines; heart failure; Left heart disease; lung disease; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; pulmonary hypertension; Respiratory failure</cfKeyw>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-62550</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-93022</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11676</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-76463</cfFedIdId>
<cfFedId>10.1093/eurheartj/ehv317</cfFedId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-62550</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-62550-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
<cfFamilyNames>Galie</cfFamilyNames>
<cfFirstNames>Nazzareno</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-93022</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-93022-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
<cfFamilyNames>Noi</cfFamilyNames>
<cfFirstNames>Autori</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11676</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11676-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2016-01-01T24:00:00</cfStartDate>
<cfFamilyNames>Ботнару</cfFamilyNames>
<cfFirstNames>В.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>